FNB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
FNB is a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is showing a constructive technical setup, analyst sentiment is positive and improving, and there is no evidence of unfavorable insider, hedge fund, or political activity. With no strong bearish catalyst in the data and the stock trading near support while trends remain bullish, I would rate it a buy today rather than waiting.
Current price is 19.05, essentially flat versus the previous close of 19.03, with only a modest regular-session decline relative to the broader market. The chart signals are supportive: MACD histogram is positive at 0.0597, RSI_6 at 55.5 is neutral-to-healthy, and the moving averages are bullish with SMA_5 > SMA_20 > SMA_200. Price is above pivot support at 18.885 and below the first resistance at 19.441, suggesting a stable short-term trend with room to move higher. The pattern-based forecast also leans positive, with upside probabilities over the next day, week, and month.
Analyst sentiment has improved repeatedly, with multiple firms raising price targets and maintaining Buy/Overweight/Outperform ratings. Regional bank M&A activity is at a seven-year high, which is supportive for sentiment in the sector. The company is scheduled to report Q2 2026 earnings on July 16, which could act as a near-term catalyst. Newsweek naming First National Bank one of America's Greatest Workplaces is a small positive brand and culture signal.
No recent politician or influential figure buying or selling was reported. Hedge funds and insiders are both neutral, and there is no recent congress trading data available.
Latest quarter information was not provided in the financial snapshot, so a direct quarter-over-quarter review is unavailable. The next reported quarter is Q2 2026, scheduled for July 16, 2026 after market close. Based on analyst previews, recent guidance commentary suggests net interest income was holding up reasonably well, fees were slightly softer, and expenses were somewhat elevated, but overall estimates have been stable to slightly improved.
Analyst trend is positive and improving. Piper Sandler raised the target to $22 and kept Overweight; BofA raised to $20 and kept Buy; Truist raised to $20 and kept Buy after Q1 results; Keefe Bruyette raised to $21 and kept Outperform. The Wall Street pros view is constructive, with more upside target revisions than downgrades and no competing bearish calls in the provided data. This is a favorable analyst backdrop for a long-term buyer.
